Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Teclistamab, a bispecific antibody targeting BCMA/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Plamotamab, a bispecific antibody targeting CD20/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Odronextamab, a bispecific antibody targeting CD20/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Epcoritamab, a bispecific antibody targeting CD20/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Glofitamab, a bispecific antibody targeting CD20/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mosunetuzumab, a bispecific antibody targeting CD20/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Blinatumomab, a bispecific antibody targeting CD19/CD3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Omburtamab, an antibody targeting B7-H3.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Naxitamab, an antibody targeting GD2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Nirsevimab, an antibody targeting RSV F protein.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Dinutuximab, an antibody targeting GD2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Lenvervimab, an antibody targeting Hepatitis B virus.